CN116251101B - Pharmaceutical composition for improving polycystic ovary syndrome and application thereof - Google Patents
Pharmaceutical composition for improving polycystic ovary syndrome and application thereof Download PDFInfo
- Publication number
- CN116251101B CN116251101B CN202310271304.0A CN202310271304A CN116251101B CN 116251101 B CN116251101 B CN 116251101B CN 202310271304 A CN202310271304 A CN 202310271304A CN 116251101 B CN116251101 B CN 116251101B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- catgut
- pharmaceutical composition
- polycystic ovary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 239000002729 catgut Substances 0.000 claims abstract description 40
- 206010062717 Increased upper airway secretion Diseases 0.000 claims abstract description 18
- 208000026435 phlegm Diseases 0.000 claims abstract description 18
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims abstract description 13
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims abstract description 13
- 241001671653 Aconitum carmichaelii Species 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 21
- 230000016087 ovulation Effects 0.000 claims description 13
- 230000027758 ovulation cycle Effects 0.000 claims description 7
- 230000003821 menstrual periods Effects 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 4
- 229940012356 eye drops Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000489492 Arisaema Species 0.000 claims description 3
- 244000197580 Poria cocos Species 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 240000006079 Schisandra chinensis Species 0.000 claims description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 2
- 240000007890 Leonurus cardiaca Species 0.000 claims description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 2
- 241000112528 Ligusticum striatum Species 0.000 claims description 2
- 241001233305 Xanthisma Species 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 229960000278 theophylline Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 21
- 238000002513 implantation Methods 0.000 abstract description 12
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 230000002175 menstrual effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 238000001467 acupuncture Methods 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000010066 hyperandrogenism Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 244000052909 Dioscorea esculenta Species 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 229960000978 cyproterone acetate Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for improving polycystic ovary syndrome and application thereof, wherein the pharmaceutical composition comprises a catgut loaded with moxifloxacin hydrochloride. The study discusses the observation of the curative effect of the acupoint catgut implantation combined Sichuan aconite phlegm guiding decoction on the patients with polycystic ovary syndrome (phlegm dampness syndrome), and the result shows that the curative effect is obviously improved.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving polycystic ovary syndrome and application thereof.
Background
Polycystic ovary syndrome (PCOS), a disease characterized by thin ovulation, high androgens, endocrine disorders and metabolic abnormalities, commonly occurring in women of childbirth age, is a common disease that results in infertility, severely affecting the quality of life, fertility and long-term health of the patient, and women of polycystic ovary syndrome have a variety of features including psychological (anxiety, depression, bodily form, etc.), reproductive (irregular menstrual cycle, hirsutism, infertility and pregnancy complications) and metabolic features (insulin resistance, metabolic syndrome, pre-diabetes, type 2 diabetes and cardiovascular risk factors). It is manifested by menoxenia, amenorrhea, hirsutism, obesity, acne, hyperandrogenism, oophoroma change, insulin resistance, and increased LH/FSH ratio. The pathogenesis of polycystic ovary syndrome is complex, mainly relates to aspects of hormone level, inflammatory reaction, insulin resistance and the like, and is mostly considered to be related to endocrine anomalies such as adrenal-pituitary-hypothalamus-ovary axis, heredity and the like. The disease diagnosis is determined based on the patient's hormonal levels, clinical manifestations and imaging manifestations. Studies have shown that obese PCOS patients are more prone to develop type 2 diabetes, atherosclerosis, cardiovascular disease, ovarian tumor, breast cancer, etc. than normal patients and are therefore becoming more and more important.
Western medicine treatment of PCOS mainly improves life style, and medicine intervenes in dacron-35, metformin and clomiphene to improve insulin resistance, reduce hyperandrogenemia and promote ovulation, and auxiliary reproduction technology or operation (laparoscope lower ovary perforation) can be adopted to assist pregnancy if necessary. The incidence rate of women in the childbirth period is higher, the treatment of PCOS patients is difficult, and the daphnetin-35 ethinyl estradiol cyproterone tablet, wherein the cyproterone acetate (CPA) has the functions of antiandrogen and progestogen, inhibits the generation of pituitary LH so as to reduce the androgens secreted by ovaries, reduces the weight and the like, achieves the treatment purpose, and reduces the blood insulin and the androgen level of the patients. In recent years, the treatment effect of the combined infertility of the Dain-35 on correcting the hyperandrogenism before ovulation promotion is remarkable, so that the secretion of androgens and luteinizing hormone before ovulation is inhibited, the menstrual cycle is regulated, the ovulation is promoted, the hair growth is effectively inhibited, and the acne is treated. Although the da ying-35 has good androgen lowering effect, the side effect is more in treating polycystic ovary syndrome, and epidemiological researches show that venous thrombosis or thrombotic diseases such as myocardial infarction, apoplexy and other diseases with extremely high risks are easy to cause. However, the drug treatment has the defects of drug withdrawal reaction, easy occurrence of ovarian hyperstimulation syndrome, unknown influence on ovarian long-term, and the like, has a certain influence on liver function after long-term administration, and the disease condition of a patient is easy to repeat and easily generates dependence after drug withdrawal for a period of time.
The disease name of polycystic ovary syndrome is not recorded in traditional Chinese medicine, and the polycystic ovary syndrome is classified into the categories of amenorrhea, irregular menstruation, infertility, abdominal mass and the like according to the clinical disease characteristics of polycystic ovary syndrome patients. Most PCOS patients show delayed menstrual cycle, even amenorrhea, hypomenorrhea, appearance with obesity or plumpness, drowsiness, limb heaviness, and vigorous skin oil secretion, and facial acne, which are consistent with phlegm-dampness syndrome. The pathogenesis of polycystic ovary syndrome is considered to be closely related to the dysfunction of liver, spleen and kidney by traditional Chinese medicine. Fu Qingzhu women's science says that "women have obesity, excessive phlegm and saliva, and can not conception … …, while obese people are wet, and excessive non-exogenous evil is also the disease in spleen and earth. … … spleen is not acceptable and is soaked in the embryo, so that the embryo is changed into a grotto in the ocean. "Zhu Danxi" put forward "fat white people have excessive phlegm and dampness" and "Yi Zong jin Jian. The key formula of gynecologic heart law" is described as: "female infertility is caused by excessive phlegm, and the lipid membrane is jammed in the cells, modern physique researches mainly show that the PCOS patient has phlegm-dampness, qi stagnation and blood stasis, wherein the most common phlegm-dampness is that Zhu Danxi indicates in Danxi heart method: "if the woman is fat, the feeling is very thick, the woman is free from drinking, and the woman cannot get a child after drinking, the woman can use phlegm-guiding soup. As can be seen from the above, excessive phlegm-dampness is an important root of the typical clinical manifestation of obesity in polycystic ovary syndrome patients.
The acupoint catgut implantation is an emerging combined treatment method by combining the acupuncture theory in the traditional Chinese medicine and the theory of the meridian theory of the traditional Chinese medicine. The absorbable catgut is buried in the acupoints by a special needle, can be used as a heterologous protein, can stimulate and induce human body to generate allergic reaction, and leads to human lymphocyte sensitization, so that the catgut is decomposed and absorbed in the body to stimulate the acupoints, smooth qi movement, dredge channels and collaterals, regulate qi and blood, and the process of the absorbable catgut in vivo absorption means that the absorbable catgut has continuous and long-lasting stimulation effect on the corresponding acupoints. In addition, the acupoint catgut implantation can activate whole body meridian through local stimulation, reduce weight, regulate lipid metabolism and improve insulin resistance, thereby achieving the purposes of regulating menstrual cycle and promoting ovulation. The acupoint catgut implantation is a special acupuncture treatment mode, and under the guidance of the Chinese medicine acupuncture meridian theory, the catgut body is implanted into the acupoint, thereby improving the body function and treating diseases. Many researches report that acupuncture and moxibustion and acupoint catgut implantation can safely and effectively treat simple obesity and polycystic ovary syndrome, and a comprehensive, effective and safe treatment mode is required because PCOS patients show typical pathological characteristics and higher long-term risks. For more than 20 years, the combination of traditional Chinese medicine and Chinese and Western medicine researches apply various traditional Chinese medicine therapies to the clinical curative effect and action mechanism of PCOS, and determine that the therapies of traditional Chinese medicine, acupuncture, acupoint catgut embedding, cupping and the like are safe and effective.
Although PCOS treatment by acupoint catgut implantation has been reported in the prior art, how to further improve the effective treatment rate is still a technical problem to be solved by those skilled in the art.
Disclosure of Invention
In order to make up the defects of the prior art, the invention aims to improve the pharmaceutical composition of polycystic ovary syndrome and application thereof. In order to achieve the purpose of the invention, the following technical scheme is adopted:
the invention provides a pharmaceutical composition for improving polycystic ovary syndrome, which comprises a catgut loaded with moxifloxacin hydrochloride.
In a preferred embodiment of the invention, the moxifloxacin hydrochloride-loaded catgut is obtained by immersing the catgut in 0.2-0.5wt% moxifloxacin hydrochloride eye drops for 5-15 minutes, taking out and airing.
In a preferred embodiment of the present invention, the pharmaceutical composition further comprises a Siberian cocklebur-attached sputum-guiding soup, which is packaged separately from the moxifloxacin hydrochloride-loaded catgut.
In a preferred embodiment of the invention, the prescription of the Sichuan aconite root phlegm guiding decoction comprises 10-15 parts by weight of rhizoma atractylodis, 10-15 parts by weight of rhizoma cyperi, 10-15 parts by weight of rhizoma pinellinae praeparata, 10-15 parts by weight of dried orange peel, 5-8 parts by weight of arisaema cum bile, 10-15 parts by weight of fried fructus aurantii, 15-20 parts by weight of poria cocos, 10-15 parts by weight of medicated leaven, 10-15 parts by weight of schisandra chinensis and 10-15 parts by weight of ginger; 10-15 parts of ligusticum wallichii and 10-15 parts of motherwort are added in menstrual period.
The invention also relates to application of the pharmaceutical composition in preparation of medicines for improving polycystic ovary syndrome.
In a preferred embodiment of the invention, the use comprises improving the menstrual cycle of the patient.
In a preferred embodiment of the invention, the use comprises improving ovulation in a patient.
In a preferred embodiment of the invention, the use comprises increasing the number of dominant follicles.
In a preferred embodiment of the invention, the moxifloxacin hydrochloride loaded catgut is embedded in the acupoints. The research selects acupoints, wherein the Ganshu and Pishu are the back Shu acupoints, have the effects of soothing liver, resolving depression, strengthening spleen and reducing phlegm, belong to the grave of bladder channels, and are also the points of three yin and any pulse of the foot, so that the regulation of thoroughfare and conception vessels, the regulation of qi and blood and the regulation of water metabolism are good; the three-foot interior is the 'closed point' of the stomach channel, is also a health care essential point, and has the effects of strengthening spleen, harmonizing stomach and eliminating dampness; three yin-channels are the three yin-channels of foot, has effects in dispersing stagnated liver qi, invigorating spleen, tonifying kidney, and regulating qi and blood; guanyuan and uterus acupoints are located in the lower abdomen and directly reach the affected part after ischemia. The Tianshu acupoint is not only the stomach meridian acupoint of foot yangming but also the large intestine meridian acupoint, and can regulate stomach and intestine, transport and transform middle energizer water metabolism, and help to lose weight. The water is an important acupoint on the conception vessel, can regulate the whole body water channel, and has the effects of transporting and transforming spleen qi, strengthening spleen and removing dampness by being matched with the Tianshu to play the role of losing weight, and the yin ling spring is the spleen meridian acupoint of foot taiyin.
The study discusses the observation of the curative effect of the acupoint catgut implantation combined Sichuan aconite phlegm guiding decoction on the patients with polycystic ovary syndrome (phlegm dampness syndrome), and the result shows that the curative effect is obviously improved.
Detailed Description
In order to further understand the present invention, a technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Unless otherwise specified, all reagents involved in the examples of the present invention are commercially available products and are commercially available.
Example 1:
1. test design
For the clinical study of the treatment of polycystic ovary syndrome (phlegm dampness syndrome) women by applying acupoint catgut implantation combined with the Sichuan aconite sputum guide decoction, PCOS patients attached to the first hospital gynecologic clinic at the university of Heilongjiang traditional Chinese medicine as a sample source are randomly divided into three groups, namely a treatment group, a control group 1 and a control group 2 according to a random digital table method.
(1) Control group 1 (30 cases) adopts catgut to perform acupoint catgut implantation and combined Sichuan aconite phlegm guiding decoction.
(2) Control group 2 (30 cases) is that catgut loaded with ofloxacin is adopted to carry out acupoint catgut implantation and combined Sichuan catheter soup.
The catgut is soaked in ofloxacin eye drops with the weight percentage of 0.3 percent for 10 minutes before the catgut is buried, taken out and dried.
(3) Treatment group (30): catgut loaded with moxifloxacin hydrochloride is adopted to carry out acupoint catgut implantation and combined Sichuan aconite phlegm guiding soup.
The catgut is soaked in 0.3wt% moxifloxacin hydrochloride eye drops for 10 minutes before the catgut is buried, taken out and dried.
The acupoint catgut implantation is carried out for 10 days for 1 time, 1 month is a treatment course, and the menstrual period stops for treatment, and the total treatment course is 3.
Acupoint selection: ganshu, pishu, tianshu, moisture, intermediate, guanyuan, uterus, zusanli, sanyinjiao and Yinlingquan are acupoint groups.
The method comprises the steps of conventionally sterilizing selected acupoints, placing a treated catgut in the front section of a disposable catgut embedding needle tube, connecting a needle core, pressing the periphery of the selected acupoints by a left hand to tighten skin, penetrating a right hand needle body into the selected acupoints, controlling the penetrating depth and the penetrating direction according to the degree of fatness of clinical patients, enabling the patient to feel a needle after the needle, embedding the catgut into subcutaneous tissue, checking whether the catgut is exposed or not, pressing for hemostasis by using a sterile cotton ball, and covering a needle hole by using a sterile band-aid.
The oral traditional Chinese medicine is taken twice a day in the morning and evening for 3 months, 10 parts of rhizoma atractylodis, 10 parts of rhizoma cyperi, 10 parts of rhizoma pinellinae praeparata, 10 parts of dried orange peel, 5 parts of arisaema cum bile, 10 parts of fructus aurantii (stir-fried), 15 parts of poria cocos, 10 parts of medicated leaven, 10 parts of schisandra chinensis and 10 parts of ginger; rhizoma Ligustici Chuanxiong 10 weight parts and herba Leonuri 10 weight parts are added during menstrual period. (the university of Heilongjiang is affiliated to the first hospital preparation room for decocting).
2. Clinical observations
(1) Symptoms and signs: recording once before and after treatment;
(2) menstrual flow conditions: observing menstrual conditions during the treatment;
disease efficacy decision criteria:
the therapeutic effect index (n) = (pre-test integral-post-test integral)/pre-test integral x 100% according to the integral method determination; the preparation method is based on the national standard of the people's republic of China, the clinical diagnosis and treatment terminology of traditional Chinese medicine, the syndrome part and the Chinese medicine new medicine clinical research guiding principle which are mainly compiled by Zhengyu, and comprises the following steps:
recovery, namely recovering menstrual cycle to be normal, eliminating main clinical symptoms, recovering serum carrier hormone to be normal, recovering glycolipid metabolism to be normal, and eliminating oophoroma change by B ultrasonic examination, wherein the curative effect index (n) is more than or equal to 90%;
the obvious effect is that the menstrual cycle is basically similar to that of normal, the improvement of main clinical symptoms is obvious, the partial disappearance or obvious alleviation of secondary symptoms is realized within 40 days, the curative effect index (n) is more than or equal to 70 percent, the serum carrier hormone and glycolipid metabolism level is recovered to be normal, and the B ultrasonic examination shows that the oophoroma change is basically disappeared;
the medicine has the advantages that menstruation is carried out for more than or equal to 1 time within 3 months, main clinical symptoms are controlled, part of secondary symptoms are reduced, the symptoms are still existing, the symptoms are reduced before treatment, the curative effect index (n) is more than or equal to 30 percent, the metabolism level of carrier hormone and glycolipid is basically recovered to be normal or is close to the normal level, and the oophoroma change is improved by B ultrasonic examination;
the menstrual period is still amenorrhea, the curative effect index (n) is less than 30%, the metabolism level of carrier hormone and glycolipid is not obviously improved, and the B ultrasonic examination shows that the oophoroma change is not improved. Or exacerbation of the condition and clinical symptoms.
3. Experimental results
Adopting SPSS18.0 software to complete statistical treatment; the counting data is checked by X2. Rank sum test is used for comparison between rank data sets. The measurement data is represented by mean ± standard deviation, and the comparison between groups is t-test; the comparison of the treatment before and after the treatment in the group adopts a paired sample t test. P <0.05 is statistically significant for the differences.
3.1 comparing the clinical curative effects, the total effective rate of the treatment group with the control group 1 and the control group 2 is respectively 90.0%, 66.7% and 76.7%; the clinical efficacy was compared between groups, and the differences were statistically significant (P < 0.05). See table 1.
Table 1 comparison of clinical efficacy
| Group of | n | Healing of the wound | Has obvious effect | Effective and effective | Invalidation of | Total effective rate (%) |
| Treatment group | 30 | 12 | 9 | 6 | 3 | 90.0％ |
| Control group 1 | 30 | 4 | 9 | 7 | 10 | 66.7％ |
| Control group 2 | 30 | 8 | 10 | 5 | 7 | 76.7％ |
3.2 menstrual condition comparison
The difference between menstrual conditions (normal and maladjusted) in the three groups was statistically significant (P < 0.05) compared to 3 months prior to treatment and after withdrawal; the comparison difference between groups is statistically significant (P < 0.05), and the treatment group improved menstrual performance over the control group. See table 2.
TABLE 2 comparison of menstrual flow before and after treatment
3.3 ovulation Change Condition
After 3 months of drug withdrawal of the three groups, comparing in the groups, the number of the three groups of dominant follicles and the ovulation rate difference are all statistically significant (P < 0.05), and the occurrence rate difference of the follicle stimulating syndrome is not statistically significant (P > 0.05); the difference of the dominant follicular numbers among the groups is statistically significant (P < 0.05), the ovulation rate is statistically significant (P < 0.05), and the effect of the treatment group on improving the ovulation rate is superior to that of the control groups 1 and 2. The results are detailed in Table 3.
TABLE 3 treatment of changes in ovulation before and after therapy
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (7)
1. A pharmaceutical composition for ameliorating polycystic ovary syndrome, the pharmaceutical composition comprising moxifloxacin hydrochloride-loaded catgut, the pharmaceutical composition further comprising a xanthium additionally ductal decoction, the xanthium additionally ductal decoction being packaged separately from moxifloxacin hydrochloride-loaded catgut; the formula of the Sichuan aconite phlegm-guiding decoction comprises 10-15 parts by weight of rhizoma atractylodis, 10-15 parts by weight of rhizoma cyperi, 10-15 parts by weight of rhizoma pinellinae praeparata, 10-15 parts by weight of dried orange peel, 5-8 parts by weight of arisaema cum bile, 10-15 parts by weight of fried fructus aurantii, 15-20 parts by weight of poria cocos, 10-15 parts by weight of medicated leaven, 10-15 parts by weight of schisandra chinensis and 10-15 parts by weight of ginger; 10-15 parts of ligusticum wallichii and 10-15 parts of motherwort are added in menstrual period.
2. The pharmaceutical composition according to claim 1, wherein the moxifloxacin hydrochloride-loaded catgut is obtained by immersing catgut in 0.2-0.5wt% moxifloxacin hydrochloride eye drops for 5-15 minutes, taking out and airing.
3. Use of a pharmaceutical composition according to claim 1 or 2 for the preparation of a medicament for ameliorating polycystic ovary syndrome.
4. The use according to claim 3, comprising improving the menstrual cycle of a patient.
5. Use according to claim 3, comprising improving ovulation in a patient.
6. The use according to claim 3, comprising increasing the number of dominant follicles.
7. The use according to any one of claims 3-6, wherein the moxifloxacin hydrochloride loaded catgut is embedded in an acupoint.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310271304.0A CN116251101B (en) | 2023-03-20 | 2023-03-20 | Pharmaceutical composition for improving polycystic ovary syndrome and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310271304.0A CN116251101B (en) | 2023-03-20 | 2023-03-20 | Pharmaceutical composition for improving polycystic ovary syndrome and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116251101A CN116251101A (en) | 2023-06-13 |
| CN116251101B true CN116251101B (en) | 2024-01-30 |
Family
ID=86687914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310271304.0A Active CN116251101B (en) | 2023-03-20 | 2023-03-20 | Pharmaceutical composition for improving polycystic ovary syndrome and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116251101B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284151A (en) * | 2007-04-11 | 2008-10-15 | 杨良机 | Production method of modified surgical catgut of point heeling-in therapy |
| CN101648019A (en) * | 2008-08-13 | 2010-02-17 | 北京和润创新医药科技发展有限公司 | Medicinal composition for treating ophthalmic inflammation and application thereof |
| CN103263696A (en) * | 2013-06-08 | 2013-08-28 | 武汉纺织大学 | Novel catgut implantation at acupoint and preparation method thereof |
-
2023
- 2023-03-20 CN CN202310271304.0A patent/CN116251101B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284151A (en) * | 2007-04-11 | 2008-10-15 | 杨良机 | Production method of modified surgical catgut of point heeling-in therapy |
| CN101648019A (en) * | 2008-08-13 | 2010-02-17 | 北京和润创新医药科技发展有限公司 | Medicinal composition for treating ophthalmic inflammation and application thereof |
| CN103263696A (en) * | 2013-06-08 | 2013-08-28 | 武汉纺织大学 | Novel catgut implantation at acupoint and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 庞国明等主编.《内分泌疾病中医特色外治256法》.中国医药科技出版社,2021,(第2021年5月第1版版),152. * |
| 苍附导痰汤联合穴位埋线治疗痰湿内阻型多囊卵巢综合征不孕的临床研究;朱丽娟等;《江西中医药大学学报》;第32卷(第5期);68-70 * |
| 陈文彦著.《实用妇科疾病诊疗》.吉林科学技术出版社,2020,(第2019年3月第2版版),78-82. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116251101A (en) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113318172A (en) | Traditional Chinese medicine composition for treating ovarian reserve function decline combined infertility and preparation method and application thereof | |
| CN100493569C (en) | Medicament for preventing and treating benign hyperplasia of mammary glands for women and preparation process thereof | |
| CN106692946A (en) | Composition for relieving vaginal relaxation, and preparation and preparing method thereof | |
| CN102302659B (en) | Chinese medicinal composition for kidney-yang deficiency and phlegm-retention type polycystic ovanian syndrome | |
| CN117180381A (en) | Traditional Chinese medicine composition for warming yang and assisting pregnancy and application and external preparation thereof | |
| CN116251101B (en) | Pharmaceutical composition for improving polycystic ovary syndrome and application thereof | |
| CN113499405B (en) | Traditional Chinese medicine composition for treating secondary amenorrhea | |
| CN100473396C (en) | Combination of medication for treating disease of hyperplasia of mammary glands glands and preparation method thereof | |
| CN104524153A (en) | Traditional Chinese medicine composition for treating perimenopausal female urethral syndrome | |
| CN114949071A (en) | Follicle-stimulating patch and preparation method thereof | |
| CN105920488A (en) | Traditional Chinese medicine leading-in liquid for coordinating with acusector and treating overactive bladder | |
| CN105214012A (en) | A kind of Chinese medicine composition for the treatment of cyclomastopathy | |
| Wang et al. | Therapeutic effect observation on treatment of acne with acupuncture plus moving cupping and blood-letting | |
| CN114146136B (en) | Traditional Chinese medicine composition for preventing postoperative uroschesis of anorectal diseases and preparation method and application thereof | |
| Chande et al. | EFFICACY OF DRAKSHAVALEHA IN PREGNANCY INDUCED CONSTIPATION | |
| Denghong | combined acupuncture-moxibustion and psychotherapy for perimenopause syndrome | |
| Liang et al. | Report of a case of infertility with infantile uterus | |
| CN110090271B (en) | Traditional Chinese medicine composition for treating male infertility, preparation and application thereof | |
| CN105688175A (en) | Traditional Chinese medicine preparation for treating polycystic ovarian syndrome | |
| Xu | Clinical Observation of 30 Cases of Postpartum Urinary Retention Treated by Painless Abdominal Acupuncture. | |
| CN103690685A (en) | Herbal foot bath powder for treating irregular menstruation of female | |
| Lee et al. | A Review of Randomized Controlled Trials of Catgut Embedding Therapy for Urinary Incontinence | |
| Flaws | Menopause and Chinese medicine | |
| Zhu et al. | Determinants of Knowledge Sharing Behaviors: Developing and Testing an Integrated Theoretical Model | |
| RU2595818C1 (en) | Method for integrated treatment of ovarian dysfunction when using hormone contraceptive "implanon" implant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |